Genmab A/S

Equities

GMAB

DK0010272202

Real-time Estimate Cboe Europe Other stock markets 07:51:27 19/01/2026 pm IST			5-day change	1st Jan Change
2,039.50 ^DKK	-6.66%		-5.55%	+0.74%

01:41pm	SHB: Overreaction in the Market to Genmab's Epkinly Study	FW
12:22pm	Genmab's Phase 3 Study with Epcoritamab Fails to Meet Overall Survival Endpoint	FW

Transcript : Genmab A/S - Shareholder/Analyst Call

Published on 03/13/2024 at 06:30 pm IST

S&P Capital IQ

Presenter Speech
Deirdre Connelly (Executives)

Good afternoon. Welcome to Genmab's 2024 Annual General Meeting. We are pleased to once again see so many of you in person, and welcome also to those of

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Genmab A/S

01:41pm	SHB: Overreaction in the Market to Genmab's Epkinly Study	FW
12:22pm	Genmab's Phase 3 Study with Epcoritamab Fails to Meet Overall Survival Endpoint	FW
10:09am	Genmab's Epcoritamab Improves Progression-free Survival in Lymphoma Patients, Phase 3 Data Shows	MT
17/01	Genmab A/S Announces Topline Results for Epcoritamab (DuoBody CD3xCD20) from Phase 3 EPCORE DLBCL-1 Trial in Patients with Relapsed Refractory Diffuse Large B-Cell Lymphoma	CI
17/01	AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma	CI
17/01	AbbVie, Genmab Lymphoma Treatment Shows Improved Progression-Free Survival	DJ
17/01	Genmab Says Epcoritamab Improves Progression-Free Survival in Phase 3 Lymphoma Study	MT
17/01	Genmab and AbbVie's blood cancer drug fails to improve survival in late-stage study	RE
17/01	Genmab says phase 3 trial for epcoritamab did not reach statistical significance	RE
17/01	Genmab's blood cancer drug fails main goal in late-stage study	RE
16/01	Genmab Stock Trading Halted, Pending Material News Release	MT
15/01	Jyske Bank Raises Genmab Target Price to 2,300 Danish Kroner (2,000), Reiterates Hold - BN	FW
14/01	Genmab A/S Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 03:45 PM
08/01	UBS Raises Price Target for Genmab to 2,750 Danish Kroner (from 2,700), Reiterates Buy	FW
08/01	Genmab A/S Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence	CI
07/01	Genmab partners with Anthropic to accelerate research and development through agentic AI	RE
07/01	Genmab to Advance R&D Processes via AI Under New Anthropic Partnership	MT
07/01	Genmab, Anthropic to Use AI Tools in Clinical Development	MT
07/01	Genmab partners with Anthropic to accelerate R&D via agentic AI	RE
30/12	Genmab Faces 'Transformative' Year Ahead With Pivotal Trial Readouts, Truist Securities Says	MT
30/12	Genmab Kept at Buy as Truist Securities Forecasts 'Transformative' Year Ahead	MT
30/12	DNB Carnegie Trims Genmab PT, Maintains Hold Rating	MT
30/12	U.S. Futures, European Stocks Mixed	DJ
30/12	SHB: Genmab's Decision to Halt Acasunlimab Development Deemed Logical	FW
30/12	Denmark's Genmab Pulls Plug on Acasunlimab to Prioritize Late-stage Clinical Assets	MT